Slammed by a trial hold, Intarcia terminates studies and axes staff in wake of an FDA rejection
Intarcia’s troubled late-stage efforts to revolutionize the way diabetes is treated has run into a fresh round of setbacks.
The Boston-based biotech — a private company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
